Bioavailability of BIIB104 Formulations in Healthy Volunteers

Phase 1, randomised, open-label trial of pesampator in schizophrenia (3 arms), sponsored by Biogen. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Time of the Last Measurable Concentration at Day 6, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity at Day 6 and 2 more. Started Dec 2021; status: completed.